Ingredient or product comparison
GHK-Cu Comparison: Mechanism and Clinical Evidence
GHK-Cu 1–2% topical Copper delivery to lysyl oxidase; collagen cross-linking; TGF-beta-1 suppression 22% in organ culture; 18.7% terminal hair density in non-responders to minoxidil 38% reduction in scalp TGF-beta-1 after 12 weeks None reported in topical form
This source-based comparison does not add ratings or recommend a winner.
- GHK-Cu 1–2% topical
- Copper delivery to lysyl oxidase; collagen cross-linking; TGF-beta-1 suppression
- 22% in organ culture; 18.7% terminal hair density in non-responders to minoxidil
- 38% reduction in scalp TGF-beta-1 after 12 weeks
- None reported in topical formulations up to 2%
- Phase II trials (n=60); multiple organ culture studies
- Minoxidil 5%
- Potassium channel opening; increased dermal blood flow; upregulation of VEGF
- 16–20% increase in anagen follicles after 16 weeks
- No direct effect on TGF-beta-1 or fibrosis pathways
- Scalp irritation (5–10% of users); rare systemic hypotension
- FDA-approved; extensive Phase III data
- Finasteride 1mg oral
- Type II 5-alpha-reductase inhibition; 70% reduction in scalp DHT
- 15–20% increase in terminal hair count after 12 months
- Indirect effect via DHT reduction; does not reverse existing fibrosis
- Sexual dysfunction (2–4% incidence); mood changes (rare)
- FDA-approved; decades of clinical use
- Microneedling 1.5mm
- Mechanical wounding induces growth factor release; increases follicle stem cell activation
- Variable (15–30% when combined with minoxidil)
- Stimulates collagen remodeling but can worsen inflammation if over-used
- Pain; transient erythema; infection risk if non-sterile
- Multiple RCTs showing synergy with minoxidil
- Bottom Line
- GHK-Cu addresses extracellular matrix degradation. A mechanism untouched by DHT blockers or vasodilators. Best evidence supports combination use rather than monotherapy, particularly in patients with advanced miniaturization where fibrosis limits other treatments.